Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy

doi:10.1002/kjm2.12303

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 高齡福祉養生管理系 > 期刊論文 > Item 310902800/34144

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34144

標題:	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy
作者:	Yeh, Ming-Lun Kuo, Hsing-Tao Huang, Ching-, I Huang, Chung-Feng Hsieh, Ming-Yen Liang, Po-Cheng Lin, I-Hung Hsieh, Meng-Hsuan Lin, Zu-Yau Chen, Shinn-Chern Dai, Chia-Yen Huang, Jee-Fu Yu, Ming-Lung Chuang, Wan-Long
貢獻者:	Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div Kaohsiung Med Univ, Coll Med, Fac Med Kaohsiung Med Univ, Coll Med, Hepatitis Res Ctr Kaohsiung Med Univ, Canc Res Ctr Kaohsiung Med Univ, Ctr Liquid Biopsy Chi Mei Med Ctr, Dept Internal Med, Div Hepatogastroenterol Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management Natl Sun Yat Sen Univ, Inst Biomed Sci Natl Chiao Tung Univ, Coll Biol Sci & Technol
關鍵字:	direct acting antivirals hepatitis C virus hepatocellular carcinoma Sorafenib survival
日期:	2021
上傳時間:	2022-11-18 11:25:50 (UTC+8)
出版者:	Wiley
摘要:	Whether patients with advanced hepatocellular carcinoma (aHCC) benefit from hepatitis C virus (HCV) eradication is uncertain. We aimed to investigate whether a survival benefit was conferred by HCV eradication in aHCC patients. This retrospective cohort study enrolled 168 HCV-infected aHCC patients from April 2013 to January 2019. All patients were treated with sorafenib. Endpoints included overall survival (OS), progression free survival (PFS), and time to liver decompensation. Patients with undetectable HCV RNA exhibited reduced aspartate aminotransferase and alpha fetoprotein levels, as well as an attenuated proportion of aHCC at initial diagnosis but increased albumin and mean sorafenib daily dosing. Patients with undetectable HCV RNA exhibited significantly longer OS compared to patients with detectable or unknown HCV RNA, which was an independent factor of OS (HR: 0.56, 95% CI: 0.350-0.903,P= .017). Patients with undetectable HCV RNA also presented a trend for longer PFS (HR 0.68, 95% CI: 0.46-1.00,P= .053). The survival benefit was considered with respect to the significantly prolonged time to Child-Pugh B scores in patients with undetectable HCV RNA (HR 0.59, 95% CI: 0.38-0.92,P= .020). Patients with detectable HCV RNA at sorafenib initiation who further received direct acting antiviral therapy also had significantly longer OS (HR 0.11, 95% CI: 0.02-0.81,P= .030) and PFS (HR 0.23, 95% CI: 0.06-0.99,P= .048). In conclusion, abolishing HCV viremia preserves liver function and confers a survival benefit in advanced HCC patients on sorafenib treatment.
關聯:	Kaohsiung Journal of Medical Sciences, v.37, n.2, pp.9
顯示於類別:	[高齡福祉養生管理系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	427	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....